Show simple item record

dc.contributor.authorLamothe-Reyes, Yaneysis
dc.contributor.authorBohórquez, José Alejandro
dc.contributor.authorWang, Miaomiao
dc.contributor.authorAlberch, Mònica
dc.contributor.authorPérez-Simó, Marta
dc.contributor.authorGanges, Llilianne
dc.contributor.authorRosell, Rosa
dc.contributor.authorGanges, Llilianne
dc.contributor.otherProducció Animalca
dc.date.accessioned2021-09-28T10:57:17Z
dc.date.available2021-09-28T10:57:17Z
dc.date.issued2021-05-06
dc.identifier.citationLamothe-Reyes, Yaneysis, José Alejandro Bohórquez, Miaomiao Wang, Mònica Alberch, Marta Pérez-Simó, Rosa Rosell, and Llilianne Ganges. 2021. "Early And Solid Protection Afforded By The Thiverval Vaccine Provides Novel Vaccination Alternatives Against Classical Swine Fever Virus". Vaccines 9 (5): 464. doi:10.3390/vaccines9050464.ca
dc.identifier.issn2076-393Xca
dc.identifier.urihttp://hdl.handle.net/20.500.12327/1358
dc.description.abstractClassical swine fever virus (CSFV) remains a challenge for the porcine industry. Inefficient vaccination programs in some endemic areas may have contributed to the emergence of low and moderate virulence CSFV variants. This work aimed to expand and update the information about the safety and efficacy of the CSFV Thiverval-strain vaccine. Two groups of pigs were vaccinated, and a contact and control groups were also included. Animals were challenged with a highly virulent CSFV strain at 21- or 5-days post vaccination (dpv). The vaccine induced rapid and strong IFN-α response, mainly in the 5-day immunized group, and no vaccine virus transmission was detected. Vaccinated pigs showed humoral response against CSFV E2 and Erns glycoproteins, with neutralising activity, starting at 14 days post vaccination (dpv). Strong clinical protection was afforded in all the vaccinated pigs as early as 5 dpv. The vaccine controlled viral replication after challenge, showing efficient virological protection in the 21-day immunized pigs despite being housed with animals excreting high CSFV titres. These results demonstrate the high efficacy of the Thiverval strain against CSFV replication. Its early protection capacity makes it a useful alternative for emergency vaccination and a consistent tool for CSFV control worldwide.ca
dc.format.extent14ca
dc.language.isoengca
dc.publisherMDPIca
dc.relation.ispartofVaccinesca
dc.rightsAttribution 4.0 Internationalca
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleEarly and Solid Protection Afforded by the Thiverval Vaccine Provides Novel Vaccination Alternatives Against Classical Swine Fever Virusca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.relation.projectIDMINECO/Programa estatal de I+D+I orientada a los retos de la sociedad/RTI2018-100887-B-100/ES/Descifrando nuevos factores virales y del hospedador involucrados en el desarrollo de la peste porcina clásica: implicaciones para el control de la enfermedad/ca
dc.subject.udc619ca
dc.identifier.doihttps://doi.org/10.3390/vaccines9050464ca
dc.contributor.groupSanitat Animalca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/